Biogen Idec (NQ: BIIB )
225.02
-1.38
(-0.61%)
Streaming Delayed Price
Updated: 2:39 PM EDT, Jul 22, 2024
Add to My Watchlist
Press Releases about Biogen Idec
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
September 29, 2023
From Biogen Inc.
Via GlobeNewswire
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
Biogen Completes Acquisition of Reata Pharmaceuticals
September 26, 2023
From Biogen Inc.
Via GlobeNewswire
![](https://www.marketbeat.com/logos/articles/med_20230925062932_are-gene-therapy-stocks-the-markets-next-big-winne.jpg)
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Via MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
Biogen Appoints Jane Grogan as Head of Research
September 06, 2023
From Biogen Inc.
Via GlobeNewswire
![](https://ml.globenewswire.com/media/aeea7200-7231-49dd-b4ba-ec680464b28c/small/brodsky-smith-logo-png-png.png)
From Brodsky & Smith LLC
Via GlobeNewswire
![](https://ml.globenewswire.com/media/aeea7200-7231-49dd-b4ba-ec680464b28c/small/brodsky-smith-logo-png-png.png)
![](https://ml.globenewswire.com/media/aeea7200-7231-49dd-b4ba-ec680464b28c/small/brodsky-smith-logo-png-png.png)
From Brodsky & Smith LLC
Via GlobeNewswire
![](https://mms.businesswire.com/media/20230804482500/en/1860268/5/Biogen_Logo_Standard.jpg)
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
![](https://ml.globenewswire.com/media/aeea7200-7231-49dd-b4ba-ec680464b28c/small/brodsky-smith-logo-png-png.png)
![](https://ml.globenewswire.com/media/aeea7200-7231-49dd-b4ba-ec680464b28c/small/brodsky-smith-logo-png-png.png)
![](https://spotlightgrowth.com/wp-content/uploads/2023/07/Reata-Pharmaceuticals-NASDAQ-RETA-Biogen-NASDAQ-BIIB-Takeover-Biotech-Spotlight-Growth.jpg)
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
![](https://www.marketbeat.com/logos/articles/med_20230719085627_acumen-soars-on-alzheimers-study.jpg)
![](https://www.marketbeat.com/logos/articles/med_20230707134150_biogen-shares-fall-after-fda-approval-of-alzheimer.jpg)
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
![](https://www.marketbeat.com/logos/articles/med_20230517121722_analysts-say-these-2-mid-cap-biotechs-have-2x-pote.jpg)
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
![](https://www.marketbeat.com/logos/articles/med_20230424135734_why-legend-biotech-stock-is-having-its-best-month.jpg)
![](https://ml.globenewswire.com/media/b52a171f-57dc-424d-8112-8d32405cff41/small/denali-t-logo-02-jpg.jpg)
![](https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg)
Biogen Appoints Adam Keeney as Head of Corporate Development
April 04, 2023
From Biogen Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.